Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003082 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer
A Phase 1 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00003082 is a Phase 1 study that has completed, run by University of Arizona. The registered enrollment target is 27 participants.
The verdict
NCT00003082, a Phase 1 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibodies in treating patients who have advanced cancer.
Interventions
- BIOLOGICAL monoclonal antibody A27.15
- BIOLOGICAL monoclonal antibody E2.3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 1997-12 |
| Est. Completion | 2001-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003082
The ClinicalTrials.gov registry entry for NCT00003082 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which monoclonal antibody A27.15 is the first listed.
NCT00003082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003082 about?
NCT00003082 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibodies in treating patients who have advanced cancer.
What is the current status of trial NCT00003082?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 1997-12. Estimated completion is 2001-02.
What interventions are being tested in trial NCT00003082?
The interventions under investigation include: monoclonal antibody A27.15 (BIOLOGICAL), monoclonal antibody E2.3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003082?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.